Cubist Pharmaceuticals (FRA:CU6) Total Tax Payable : €0.0 Mil (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Cubist Pharmaceuticals Total Tax Payable?

Cubist Pharmaceuticals's Total Tax Payable for the quarter that ended in Sep. 2014 was €0.0 Mil.

Cubist Pharmaceuticals Total Tax Payable Historical Data

The historical data trend for Cubist Pharmaceuticals's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cubist Pharmaceuticals Total Tax Payable Chart

Cubist Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Total Tax Payable

Get a 7-Day Free Trial

Cubist Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

Cubist Pharmaceuticals Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Cubist Pharmaceuticals Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Cubist Pharmaceuticals's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cubist Pharmaceuticals (FRA:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cubist Pharmaceuticals Inc (FRA:CU6) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cubist.com

Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.

Cubist Pharmaceuticals (FRA:CU6) Headlines

No Headlines